Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
NURO's Cash to Debt is ranked higher than
95% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.56 vs. NURO: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NURO' s Cash to Debt Range Over the Past 10 Years
Min: 0.63  Med: 1191.9 Max: No Debt
Current: No Debt
Equity to Asset 0.79
NURO's Equity to Asset is ranked higher than
80% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. NURO: 0.79 )
Ranked among companies with meaningful Equity to Asset only.
NURO' s Equity to Asset Range Over the Past 10 Years
Min: -6.3  Med: 0.79 Max: 0.91
Current: 0.79
-6.3
0.91
Interest Coverage No Debt
NURO's Interest Coverage is ranked higher than
95% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.78 vs. NURO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NURO' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.5 Max: No Debt
Current: No Debt
N/A
No Debt
F-Score: 3
Z-Score: -16.50
M-Score: -2.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -154.96
NURO's Operating margin (%) is ranked lower than
88% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. NURO: -154.96 )
Ranked among companies with meaningful Operating margin (%) only.
NURO' s Operating margin (%) Range Over the Past 10 Years
Min: -181.86  Med: -110.37 Max: 5.18
Current: -154.96
-181.86
5.18
Net-margin (%) -145.21
NURO's Net-margin (%) is ranked lower than
86% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.53 vs. NURO: -145.21 )
Ranked among companies with meaningful Net-margin (%) only.
NURO' s Net-margin (%) Range Over the Past 10 Years
Min: -151.9  Med: -108.76 Max: 7.72
Current: -145.21
-151.9
7.72
ROE (%) -431.67
NURO's ROE (%) is ranked lower than
98% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.19 vs. NURO: -431.67 )
Ranked among companies with meaningful ROE (%) only.
NURO' s ROE (%) Range Over the Past 10 Years
Min: -431.67  Med: -71.77 Max: 10.91
Current: -431.67
-431.67
10.91
ROA (%) -98.11
NURO's ROA (%) is ranked lower than
97% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. NURO: -98.11 )
Ranked among companies with meaningful ROA (%) only.
NURO' s ROA (%) Range Over the Past 10 Years
Min: -98.11  Med: -58.46 Max: 8.66
Current: -98.11
-98.11
8.66
ROC (Joel Greenblatt) (%) -2147.08
NURO's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.92 vs. NURO: -2147.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NURO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3242.14  Med: -513.34 Max: 124.95
Current: -2147.08
-3242.14
124.95
Revenue Growth (3Y)(%) -44.60
NURO's Revenue Growth (3Y)(%) is ranked lower than
96% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NURO: -44.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NURO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.4  Med: -35.05 Max: 4.2
Current: -44.6
-63.4
4.2
EBITDA Growth (3Y)(%) -38.10
NURO's EBITDA Growth (3Y)(%) is ranked lower than
96% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. NURO: -38.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NURO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.5  Med: -34.85 Max: 8.7
Current: -38.1
-59.5
8.7
EPS Growth (3Y)(%) -28.10
NURO's EPS Growth (3Y)(%) is ranked lower than
86% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.00 vs. NURO: -28.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NURO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.7  Med: -36.9 Max: 3.6
Current: -28.1
-53.7
3.6
» NURO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-22)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

NURO Guru Trades in Q3 2015

Jim Simons 125,300 sh (+64.01%)
» More
Q4 2015

NURO Guru Trades in Q4 2015

Jim Simons 36,700 sh (+17.16%)
» More
Q1 2016

NURO Guru Trades in Q1 2016

Jim Simons 57,700 sh (+57.22%)
» More
Q2 2016

NURO Guru Trades in Q2 2016

Jim Simons 53,900 sh (-6.59%)
» More
» Details

Insider Trades

Latest Guru Trades with NURO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:OTCPK:LDSYF, NAS:SSKN, OTCPK:PEYE, OTCPK:IRSB, OTCPK:RSCF, OTCPK:ECIA, OTCPK:STXS, OTCPK:SOAN, NAS:SKLN, OTCPK:REPR, OTCPK:UEEC, OTCPK:ASNB, OTCPK:WHSI, OTCPK:QTXB, OTCPK:GNID, OTCPK:SECI, NAS:DXTR, NAS:AKER, OTCBB:NEPH, NAS:PDEX » details
Traded in other countries:NLZC.Germany,
NeuroMetrix Inc manufactures and sells wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests that help patients and physicians manage chronic pain, nerve diseases, and sleep disorders.

NeuroMetrix Inc was incorporated in Delaware in June 1996. The Company is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company develops and markets neurodiagnostic systems which consist of a medical device plus single patient-use biosensors or electrodes. Other accessories are also offered to its customers. The Company's product portfolio includes NC-stat DPN check for Diabetes Diagnostics; Sensus for Pain Management and Advance NCS/EMG System for Orthopedics & Neurology. NC-stat DPNCheck is a fast, accurate, and quantitative nerve conduction test that is used to evaluate systemic neuropathies such as DPN. It is designed to be used by primary care physicians, endocrinologists, podiatrists and other clinicians at the point-of-care to objectively detect, stage, and monitor DPN. The device measures nerve conduction velocity and response amplitude of the sural nerve, a nerve in the lower leg and ankle. These parameters are recognized as sensitive and specific biomarkers of DPN. The Company also markets a medical device, which has been cleared by the FDA and which is used for the assessment of neuropathies such as carpal tunnel syndrome, diabetes, and sciatica. Its ADVANCE NCS/EMG System, or the ADVANCE System, which is a part of its legacy neurodiagnostics business, is a comprehensive platform for the performance of traditional nerve conduction studies and invasive electromyography procedures. Its ADVANCE System is comprised of; various types of electrodes and needles, its ADVANCE device and related modules, and a communication hub that enables the physician's office to network their device to its servers for data archiving, report generation and other network services. The Company competes with CareFusion Corporation, Cadwell Laboratories, Inc., and Natus Medical Incorporated. The Company's products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the regulations promulgated thereunder, as well as by other regulatory bodies in the United States and abroad.

Top Ranked Articles about NeuroMetrix Inc

NeuroMetrix Officer Acquires 12,000 Shares CEO invests in health care company
Shai Gozani (Insider Trades), CEO and president of NeuroMetrix Inc. (NURO), acquired 12,000 shares in the company on May 19. The average price per share was $1.55 for a total transaction of $18,600. Read more...

Ratios

vs
industry
vs
history
P/B 0.70
NURO's P/B is ranked higher than
93% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. NURO: 0.70 )
Ranked among companies with meaningful P/B only.
NURO' s P/B Range Over the Past 10 Years
Min: 0.27  Med: 0.98 Max: 13.56
Current: 0.7
0.27
13.56
P/S 0.57
NURO's P/S is ranked higher than
91% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. NURO: 0.57 )
Ranked among companies with meaningful P/S only.
NURO' s P/S Range Over the Past 10 Years
Min: 0.2  Med: 0.97 Max: 12.99
Current: 0.57
0.2
12.99
EV-to-EBIT 0.20
NURO's EV-to-EBIT is ranked higher than
99% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.20 vs. NURO: 0.20 )
Ranked among companies with meaningful EV-to-EBIT only.
NURO' s EV-to-EBIT Range Over the Past 10 Years
Min: -352.3  Med: 0.2 Max: 6259.2
Current: 0.2
-352.3
6259.2
EV-to-EBITDA 0.20
NURO's EV-to-EBITDA is ranked higher than
99% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.23 vs. NURO: 0.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
NURO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -801.5  Med: 0.3 Max: 541.5
Current: 0.2
-801.5
541.5
Current Ratio 4.74
NURO's Current Ratio is ranked higher than
82% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. NURO: 4.74 )
Ranked among companies with meaningful Current Ratio only.
NURO' s Current Ratio Range Over the Past 10 Years
Min: 2.29  Med: 5.27 Max: 13.01
Current: 4.74
2.29
13.01
Quick Ratio 4.38
NURO's Quick Ratio is ranked higher than
85% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.64 vs. NURO: 4.38 )
Ranked among companies with meaningful Quick Ratio only.
NURO' s Quick Ratio Range Over the Past 10 Years
Min: 1.79  Med: 4.85 Max: 12.52
Current: 4.38
1.79
12.52
Days Inventory 75.16
NURO's Days Inventory is ranked higher than
79% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.57 vs. NURO: 75.16 )
Ranked among companies with meaningful Days Inventory only.
NURO' s Days Inventory Range Over the Past 10 Years
Min: 75.16  Med: 134.07 Max: 246.22
Current: 75.16
75.16
246.22
Days Sales Outstanding 12.36
NURO's Days Sales Outstanding is ranked higher than
96% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.25 vs. NURO: 12.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
NURO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.36  Med: 39.31 Max: 50.86
Current: 12.36
12.36
50.86
Days Payable 40.78
NURO's Days Payable is ranked lower than
61% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 48.01 vs. NURO: 40.78 )
Ranked among companies with meaningful Days Payable only.
NURO' s Days Payable Range Over the Past 10 Years
Min: 8.14  Med: 53.2 Max: 97.92
Current: 40.78
8.14
97.92

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -95.70
NURO's 3-Year Average Share Buyback Ratio is ranked lower than
97% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. NURO: -95.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NURO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -134.3  Med: -72.85 Max: -3.6
Current: -95.7
-134.3
-3.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.95
NURO's Price/Net Cash is ranked higher than
96% of the 50 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.23 vs. NURO: 0.95 )
Ranked among companies with meaningful Price/Net Cash only.
NURO' s Price/Net Cash Range Over the Past 10 Years
Min: 0.67  Med: 2.07 Max: 19.81
Current: 0.95
0.67
19.81
Price/Net Current Asset Value 0.73
NURO's Price/Net Current Asset Value is ranked higher than
98% of the 116 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.50 vs. NURO: 0.73 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NURO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.46  Med: 1.54 Max: 18.67
Current: 0.73
0.46
18.67
Price/Tangible Book 0.68
NURO's Price/Tangible Book is ranked higher than
94% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.58 vs. NURO: 0.68 )
Ranked among companies with meaningful Price/Tangible Book only.
NURO' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.43  Med: 1.42 Max: 13.39
Current: 0.68
0.43
13.39
Price/Median PS Value 0.59
NURO's Price/Median PS Value is ranked higher than
86% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.18 vs. NURO: 0.59 )
Ranked among companies with meaningful Price/Median PS Value only.
NURO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.35  Med: 1.28 Max: 12.96
Current: 0.59
0.35
12.96
Earnings Yield (Greenblatt) (%) 476.82
NURO's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.90 vs. NURO: 476.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NURO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 253.1 Max: 4742.6
Current: 476.82
0.1
4742.6

More Statistics

Revenue (TTM) (Mil) $9.71
EPS (TTM) $ -11.08
Beta0.74
Short Percentage of Float5.84%
52-Week Range $1.35 - 3.72
Shares Outstanding (Mil)5.12

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 11 18
EPS ($) -7.67 -0.93
EPS w/o NRI ($) -7.67 -0.93
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NURO

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlights Sep 07 2016 
NeuroMetrix Officer Acquires 12,000 Shares May 23 2016 
NeuroMetrix Inc. (NURO) CEO Shai Gozani buys 200,000 Shares Nov 18 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) Nov 09 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) Aug 10 2010 
NeuroMetrix Inc. Reports Operating Results (10-Q) May 14 2010 
NeuroMetrix Inc. (NURO) CEO Shai Gozani buys 100,000 Shares Mar 03 2009 

More From Other Websites
NeuroMetrix Announces Quell Fibromyalgia Pilot with Synovation Medical Group Sep 22 2016
NeuroMetrix Announces Quell Fibromyalgia Pilot with Synovation Medical Group Sep 22 2016
NeuroMetrix Reports Progress on Quell Availability within the Veterans Health Administration Sep 20 2016
NeuroMetrix Reports Progress on Quell Availability within the Veterans Health Administration Sep 20 2016
NeuroMetrix Wins Electronics Retailer Association Award for Quell TV Advertising Sep 16 2016
NeuroMetrix Reports Final Approval to Market DPNCheck in China Sep 13 2016
NeuroMetrix Reports Final Approval to Market DPNCheck in China Sep 13 2016
NeuroMetrix Announces Quell Dispensing Partnership with Comprehensive Pain Specialists Sep 08 2016
NeuroMetrix Announces Quell Dispensing Partnership with Comprehensive Pain Specialists Sep 08 2016
Weekly CFO Buys Highlights Sep 07 2016
NeuroMetrix Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference... Sep 06 2016
NeuroMetrix Announces Issuance of Patent for DPNCheck Core Technology in China Sep 01 2016
NeuroMetrix Announces Issuance of Patent for DPNCheck Core Technology in China Sep 01 2016
NeuroMetrix Announces Issuance of Patent for DPNCheck Core Technology in China Sep 01 2016
NeuroMetrix Launches New Website to Support Growth of Quell Wearable Pain Relief Technology Aug 30 2016
NeuroMetrix Launches New Website to Support Growth of Quell Wearable Pain Relief Technology Aug 30 2016
NeuroMetrix Announces That Quell Will Be Featured in the Target Open House Aug 25 2016
NeuroMetrix Celebrates 10,000 Quell Facebook Fans with Pain Awareness Month Contest Aug 22 2016
NeuroMetrix Commentary on Strategic and Business Partnerships for Quell Wearable Pain Relief... Aug 16 2016
NeuroMetrix Commentary on Strategic and Business Partnerships for Quell Wearable Pain Relief... Aug 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)